327 related articles for article (PubMed ID: 22272226)
1. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells.
Yin P; Roqueiro D; Huang L; Owen JK; Xie A; Navarro A; Monsivais D; Coon JS; Kim JJ; Dai Y; Bulun SE
PLoS One; 2012; 7(1):e29021. PubMed ID: 22272226
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells.
Yin P; Lin Z; Reierstad S; Wu J; Ishikawa H; Marsh EE; Innes J; Cheng Y; Pearson K; Coon JS; Kim JJ; Chakravarti D; Bulun SE
Cancer Res; 2010 Feb; 70(4):1722-30. PubMed ID: 20124487
[TBL] [Abstract][Full Text] [Related]
3. Ovarian steroid hormones modulate the expression of progesterone receptors and histone acetylation patterns in uterine leiomyoma cells.
Sant'Anna GDS; Brum IS; Branchini G; Pizzolato LS; Capp E; Corleta HVE
Gynecol Endocrinol; 2017 Aug; 33(8):629-633. PubMed ID: 28300476
[TBL] [Abstract][Full Text] [Related]
4. PLIN2 Functions As a Novel Link Between Progesterone Signaling and Metabolism in Uterine Leiomyoma Cells.
Okeigwe I; Bulun S; Liu S; Rademaker AW; Coon JS; Kujawa S; Robins J; Yin P
J Clin Endocrinol Metab; 2019 Dec; 104(12):6256-6264. PubMed ID: 31504629
[TBL] [Abstract][Full Text] [Related]
5. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells.
Luo X; Yin P; Reierstad S; Ishikawa H; Lin Z; Pavone ME; Zhao H; Marsh EE; Bulun SE
J Clin Endocrinol Metab; 2009 Nov; 94(11):4533-9. PubMed ID: 19808856
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells.
Yin P; Lin Z; Cheng YH; Marsh EE; Utsunomiya H; Ishikawa H; Xue Q; Reierstad S; Innes J; Thung S; Kim JJ; Xu E; Bulun SE
J Clin Endocrinol Metab; 2007 Nov; 92(11):4459-66. PubMed ID: 17785366
[TBL] [Abstract][Full Text] [Related]
7. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2/Beclin1-dependent mechanism.
Zhang L; Feng Q; Wang Z; Liu P; Cui S
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262976
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma.
Liu S; Yin P; Kujawa SA; Coon JS; Okeigwe I; Bulun SE
Oncogene; 2019 Apr; 38(15):2722-2735. PubMed ID: 30538295
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Lin VC; Aw SE; Ng EH; Ng EH; Tan MG
Br J Cancer; 2001 Dec; 85(12):1978-86. PubMed ID: 11747343
[TBL] [Abstract][Full Text] [Related]
11. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation.
Gass EK; Leonhardt SA; Nordeen SK; Edwards DP
Endocrinology; 1998 Apr; 139(4):1905-19. PubMed ID: 9528977
[TBL] [Abstract][Full Text] [Related]
12. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
Rojas PA; May M; Sequeira GR; Elia A; Alvarez M; Martínez P; Gonzalez P; Hewitt S; He X; Perou CM; Molinolo A; Gibbons L; Abba MC; Gass H; Lanari C
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376177
[TBL] [Abstract][Full Text] [Related]
13. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors.
Beck CA; Estes PA; Bona BJ; Muro-Cacho CA; Nordeen SK; Edwards DP
Endocrinology; 1993 Aug; 133(2):728-40. PubMed ID: 8344212
[TBL] [Abstract][Full Text] [Related]
14. Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential.
Feng Q; Crochet JR; Dai Q; Leppert PC; Price TM
J Clin Endocrinol Metab; 2014 Mar; 99(3):E390-9. PubMed ID: 24423317
[TBL] [Abstract][Full Text] [Related]
15. LAT1 regulates growth of uterine leiomyoma smooth muscle cells.
Xia Luo ; Coon JS; Su E; Pearson EK; Ping Yin ; Ishikawa H; Bulun SE
Reprod Sci; 2010 Sep; 17(9):791-7. PubMed ID: 20601542
[TBL] [Abstract][Full Text] [Related]
16. Systematic analysis of gene expression pattern in has-miR-197 over-expressed human uterine leiomyoma cells.
Ling J; Wu X; Fu Z; Tan J; Xu Q
Biomed Pharmacother; 2015 Oct; 75():226-33. PubMed ID: 26311392
[TBL] [Abstract][Full Text] [Related]
17. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor.
Beck CA; Zhang Y; Weigel NL; Edwards DP
J Biol Chem; 1996 Jan; 271(2):1209-17. PubMed ID: 8557652
[TBL] [Abstract][Full Text] [Related]
18. Mifepristone inhibits extracellular matrix formation in uterine leiomyoma.
Patel A; Malik M; Britten J; Cox J; Catherino WH
Fertil Steril; 2016 Apr; 105(4):1102-10. PubMed ID: 26776909
[TBL] [Abstract][Full Text] [Related]
19. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines.
Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D
Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427
[TBL] [Abstract][Full Text] [Related]
20. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK
Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
